Clinical Trial Update: GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for a GASC1 inhibitor caffeic acid in stage III esophageal cancer (squamous cell) is reported with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• GASC1 inhibitor caffeic acid
• caffeic acid

Snippet

Sponsor: The First Affiliated Hospital of Henan University of Science and Technology | Conditions: Esophagus Cancer, Stage III | Phase 3 | Status: UNKNOWN